Skip to main content
LIFECOME BIOCHEMISTRY CO., LTD. logo

LIFECOME BIOCHEMISTRY CO., LTD. — Investor Relations & Filings

Ticker · 002868 ISIN · CNE100002QH2 LEI · 65560089EP03NANEN790 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,742 across all filing types
Latest filing 2025-11-13 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002868

About LIFECOME BIOCHEMISTRY CO., LTD.

https://www.pclifecome.com

Lifecome Biochemistry Co., Ltd. focuses on the research, development, and large-scale production of fermentation-based veterinary pharmaceuticals and feed additives. The company’s core product portfolio includes Bacitracin Zinc, Bacitracin Methylene Disalicylate (BMD), and Colistin Sulfate, available in both active pharmaceutical ingredient (API) and premix forms. These biochemical products are primarily utilized in the livestock and poultry sectors to manage enteric health and improve feed efficiency. The organization operates advanced fermentation and purification facilities, maintaining compliance with international Good Manufacturing Practices (GMP) and various global regulatory standards. By leveraging specialized biotechnological processes, the company provides high-purity solutions aimed at enhancing animal nutrition and disease prevention across international markets.

Recent filings

Filing Released Lang Actions
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a stock trading abnormal fluctuation announcement by the company 绿康生化股份有限公司. It discusses the company's financial difficulties, risk warnings, stock price volatility, shareholder changes, and potential delisting risks. It references the 2024 annual report and recent financial data but does not contain the full annual report or detailed financial statements itself. The document is relatively short (2981 characters) and serves as a regulatory disclosure about stock trading abnormalities and risk warnings rather than a full financial report. Therefore, it fits best as a Regulatory Filing (RNS) rather than an Annual Report (10-K) or Delisting Announcement (DLST), since it is primarily an abnormal stock trading notice with risk disclosures and shareholder information, not a formal delisting notice or full report.
2025-11-13 Chinese
承诺参加最近一次独董培训的书面承诺
Regulatory Filings
2025-11-13 Chinese
绿康生化股份有限公司独立董事候选人声明与承诺
Board/Management Information Classification · 95% confidence The document is a detailed declaration and commitment statement by an independent director candidate for a company's board. It includes statements of qualifications, compliance with laws and regulations, and commitments related to the role of an independent director. There are no financial statements, earnings data, or report summaries. The content focuses on board/management information, specifically about a director candidate's qualifications and declarations. This fits the category of Board/Management Information (MANG), which covers announcements related to changes or appointments in the company's board of directors or senior management.
2025-11-13 Chinese
关于补选公司独立董事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election of an independent director to the company's board. It details the resignation of a previous independent director and the nomination of a new candidate, including compliance with relevant laws and regulations. There is no financial data, earnings information, or report publication mentioned. The content focuses on board/management changes, specifically the appointment of a new independent director. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS.
2025-11-13 Chinese
绿康生化股份有限公司独立董事提名人声明与承诺
Board/Management Information Classification · 95% confidence The document is a formal statement and commitment by a nominator regarding the nomination of an independent director candidate for the company's board. It details the qualifications, compliance with laws and regulations, and independence criteria of the nominee. There is no financial data, no report of financial performance, no voting results, no management changes announcement, and no mention of a meeting or call transcript. The document is a regulatory compliance statement related to board nomination, not a report or announcement of a meeting or vote. It fits best under Board/Management Information (MANG) as it concerns the nomination of a board member.
2025-11-13 Chinese
第五届董事会第二十五次（临时）会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a specific board meeting of the company, including details about the meeting date, attendance, and decisions made such as the nomination of an independent director and proposals for a shareholders meeting. It does not contain financial statements or detailed financial performance data. It is not a full annual or interim report, nor an earnings release. It is not a call transcript or investor presentation. The content focuses on board meeting decisions and governance matters. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2025-11-13 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.